CUE VS OPNT Stock Comparison

Performance

CUE
10/100

CUE returned -33.33% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

OPNT
52/100

OPNT returned -25.67% in the last 12 months. Based on the other stocks in it's sector with an average return of -26.27%, it's performance is above average giving it a grade of 52 of 100.

Analyst Price Targets

CUE
75/100

1 analysts offer 12-month price targets for CUE. Together, they have an average target of 7, the most optimistic target put CUE at 7 within 12-months and the most pessimistic has CUE at 7.

OPNT

"Analyst Price Targets" not found for OPNT

Sentiment

CUE
74/100

CUE had a bullish sentiment score of 74.32% across Twitter and StockTwits over the last 12 months. It had an average of 2.59 posts, 1.65 comments, and 3.88 likes per day.

OPNT
72/100

OPNT had a bullish sentiment score of 71.59% across Twitter and StockTwits over the last 12 months. It had an average of 4.93 posts, 0.34 comments, and 0.59 likes per day.

Technicals

CUE
64/100

CUE receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

OPNT
50/100

OPNT receieves a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

CUE
10/100

CUE has missed earnings 6 times in the last 20 quarters.

OPNT
10/100

OPNT has missed earnings 6 times in the last 20 quarters.

Profit

CUE
10/100

Out of the last 20 quarters, CUE has had 0 profitable quarters and has increased their profits year over year on 0 of them.

OPNT
44/100

Out of the last 19 quarters, OPNT has had 9 profitable quarters and has increased their profits year over year on 5 of them.

Volatility

CUE
40/100

CUE has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

OPNT
59/100

OPNT has had a higher than average amount of volatility over the last 12 months giving it a grade of 58 of 100.

Forecast

CUE

"Forecast" not found for CUE

OPNT
75/100

1 analysts offer 12-month price forecasts for OPNT. Together, they have an average target of 0, the most optimistic forecast put OPNT at 0 within 12-months and the most pessimistic has OPNT at 0.

Dividend

CUE

"Dividend" not found for CUE

OPNT
10/100

OPNT has not paid a dividend in the last 5 years.

All score calculations are broken down here to help you make more informed investing decisions

Cue Biopharma, Inc. Summary

Nasdaq / CUE

Healthcare

Biotechnology

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Opiant Pharmaceuticals, Inc. Common Stock Summary

Nasdaq / OPNT

Healthcare

Biotechnology

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.

Power up your portfolio